[1] GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020; 395, 709−33. doi:  10.1016/S0140-6736(20)30045-3
[2] Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int, 2018; 94, 567−81. doi:  10.1016/j.kint.2018.04.011
[3] Menè P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens, 2008; 26, 2085-92.
[4] Bellomo G. The relationship between uric acid, allopurinol, cardiovascular events, and kidney disease progression: a step forward. Am J Kidney Dis, 2015; 65, 525−7. doi:  10.1053/j.ajkd.2015.01.001
[5] Kuma A, Mafune K, Uchino B, et al. Alteration of normal level of serum urate may contribute to decrease in estimated glomerular filtration rate decline in healthy Japanese men. Ren Fail, 2021; 43, 1408−15. doi:  10.1080/0886022X.2021.1988969
[6] Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict? J Nephrol, 2020; 33, 715-24.
[7] Yang C, Ma X, Zhao W, et al. A longitudinal analysis of the relationship between serum uric acid and residual renal function loss in peritoneal dialysis patients. Ren Fail, 2020; 42, 447−54. doi:  10.1080/0886022X.2020.1761387
[8] Mwasongwe SE, Fülöp T, Katz R, et al. Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study. J Clin Hypertens (Greenwich), 2018; 20, 775−83. doi:  10.1111/jch.13239
[9] Takae K, Nagata M, Hata J, et al. Serum uric acid as a risk factor for chronic kidney disease in a Japanese community- the Hisayama study. Circulat J, 2016; 80, 1857−62. doi:  10.1253/circj.CJ-16-0030
[10] Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis, 2007; 50, 239−47. doi:  10.1053/j.ajkd.2007.05.013
[11] Madero M, Sarnak MJ, Wang XL, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis, 2009; 53, 796−803. doi:  10.1053/j.ajkd.2008.12.021
[12] Weaver DJ. Uric acid and progression of chronic kidney disease. Pediatr Nephrol, 2019; 34, 801−9. doi:  10.1007/s00467-018-3979-2
[13] Zhao YH, Hu YS, Smith JP, et al. Cohort profile: the China health and retirement longitudinal study (CHARLS). Int J Epidemiol, 2014; 43, 61−8. doi:  10.1093/ije/dys203
[14] Cheng HT, Huang JW, Chiang CK, et al. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J Clin Endocrinol Metab, 2012; 97, 1268−76. doi:  10.1210/jc.2011-2658
[15] Cao X, Wu LX, Chen ZH. The association between elevated serum uric acid level and an increased risk of renal function decline in a health checkup cohort in China. Int Urol Nephrol, 2018; 50, 517−25. doi:  10.1007/s11255-017-1732-6
[16] Shlipak MG, Katz R, Kestenbaum B, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol, 2009; 20, 2625−30. doi:  10.1681/ASN.2009050546
[17] Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med, 2008; 168, 2212−8. doi:  10.1001/archinte.168.20.2212
[18] Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med, 2012; 367, 20−9. doi:  10.1056/NEJMoa1114248
[19] Ye MY, Hu K, Jin J, et al. The association between time-mean serum uric acid levels and the incidence of chronic kidney disease in the general population: a retrospective study. BMC Nephrol, 2018; 19, 190. doi:  10.1186/s12882-018-0982-6
[20] Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA, 2011; 305, 1553−9. doi:  10.1001/jama.2011.451
[21] Kugler E, Cohen E, Goldberg E, et al. C reactive protein and long-term risk for chronic kidney disease: a historical prospective study. J Nephrol, 2015; 28, 321−7. doi:  10.1007/s40620-014-0116-6
[22] Stöhr E, Aksoy A, Campbell M, et al. Hospital admissions during Covid-19 lock-down in Germany: Differences in discretionary and unavoidable cardiovascular events. PLoS One, 2020; 15, e0242653. doi:  10.1371/journal.pone.0242653
[23] Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol, 2011; 7, 11−21. doi:  10.1038/nrneph.2010.154
[24] Zhang XX, Kong J, Yun K. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies. J Diabetes Res, 2020; 2020, 2315607.
[25] Sharma G, Dubey A, Nolkha N, et al. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis, 2021; 13, 1759720x211016661.
[26] Hsieh YP, Chang CC, Yang Y, et al. The role of uric acid in chronic kidney disease patients. Nephrology (Carlton, Vic), 2017; 22, 441−8. doi:  10.1111/nep.12679
[27] Kim WJ, Kim SS, Bae MJ, et al. High-normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function. J Diabetes Complicat, 2014; 28, 130−4. doi:  10.1016/j.jdiacomp.2013.11.006
[28] Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol, 2008; 3, 706−13. doi:  10.2215/CJN.04271007
[29] Zhang LX, Wang F, Wang XY, et al. The association between plasma uric acid and renal function decline in a Chinese population-based cohort. Nephrol Dial Transplant, 2012; 27, 1836−9. doi:  10.1093/ndt/gfr597
[30] Siu YP, Leung KT, Tong MKH, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis, 2006; 47, 51−9. doi:  10.1053/j.ajkd.2005.10.006
[31] Lambert EA, Hachem M, Hemmes R, et al. Serum uric acid and the relationship with subclinical organ damage in adults. J Hypertens, 2017; 35, 745−52. doi:  10.1097/HJH.0000000000001212
[32] Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension, 2003; 41, 1287−93. doi:  10.1161/01.HYP.0000072820.07472.3B
[33] Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 1998; 2, 275−81. doi:  10.1016/S1097-2765(00)80139-2
[34] Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension, 2001; 38, 1101−6. doi:  10.1161/hy1101.092839
[35] Masi S, Georgiopoulos G, Alexopoulos G, et al. The complex relationship between serum uric acid, endothelial function and small vessel remodeling in humans. J Clin Med, 2020; 9, 2027. doi:  10.3390/jcm9072027
[36] Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int, 2005; 67, 237−47. doi:  10.1111/j.1523-1755.2005.00074.x
[37] Kanbay M, Girerd N, Machu JL, et al. Impact of uric acid on hypertension occurrence and target organ damage: insights from the STANISLAS cohort with a 20-year follow-up. Am J Hypertens, 2020; 33, 869−78. doi:  10.1093/ajh/hpaa030
[38] Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care, 2009; 32, 1737−42. doi:  10.2337/dc09-0288
[39] Akasaka H, Yoshida H, Takizawa H, et al. The impact of elevation of serum uric acid level on the natural history of glomerular filtration rate (GFR) and its sex difference. Nephrol Dial Transplant, 2014; 29, 1932−9. doi:  10.1093/ndt/gfu197
[40] Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis, 2004; 44, 642−50. doi:  10.1016/S0272-6386(04)00934-5
[41] Bravo RC, Gamo MB, Lee HH, et al. Investigating serum uric acid as a risk factor in the development of delayed renal recovery in living kidney donors. Transplant Proc, 2017; 49, 930−4. doi:  10.1016/j.transproceed.2017.03.034
[42] Preitner F, Bonny O, Laverrière A, et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA, 2009; 106, 15501−6. doi:  10.1073/pnas.0904411106
[43] Gades MD, Stern JS, van Goor H, et al. Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int, 1998; 53, 130−5. doi:  10.1046/j.1523-1755.1998.00746.x
[44] Stier CT Jr, Chander PN, Rosenfeld L, et al. Estrogen promotes microvascular pathology in female stroke-prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab, 2003; 285, E232−9. doi:  10.1152/ajpendo.00029.2003
[45] Zhou MY, Zhang XL, Wen XY, et al. Development of a functional glomerulus at the organ level on a chip to mimic hypertensive nephropathy. Sci Rep, 2016; 6, 31771. doi:  10.1038/srep31771
[46] Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother, 2010; 11, 2675−86. doi:  10.1517/14656566.2010.485612
[47] Mennuni S, Rubattu S, Pierelli G, et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens, 2014; 28, 74−9. doi:  10.1038/jhh.2013.55
[48] Koch EAT, Nakhoul R, Nakhoul F, et al. Autophagy in diabetic nephropathy: a review. Int Urol Nephrol, 2020; 52, 1705−12. doi:  10.1007/s11255-020-02545-4
[49] Wang M, Li JJ, Li Y, et al. The effects of hypertension and diabetes on new-onset chronic kidney disease: A prospective cohort study. J Clin Hypertens, 2020; 22, 39−46. doi:  10.1111/jch.13768
[50] De Cosmo S, Viazzi F, Pacilli A, et al. Serum uric acid and risk of CKD in type 2 diabetes. Clin J Am Soc Nephrol, 2015; 10, 1921−9. doi:  10.2215/CJN.03140315